Ben Steinmetz comes to Persevere with a wealth of pharmaceutical experience and oncology expertise. Since 2018, he has functioned as a fractional Chief Commercial Officer, as he is doing for Persevere, for several pre-commercial and launch phase oncology companies.

In 2015, Ben joined Churchill Pharmaceuticals as SVP Commercial, leading the launch effort for a new oral anticancer agent in a >$4 billion market. Prior to Churchill, he was VP Reimbursement and Patient Access for GlaxoSmithKline and VP Policy and Payer Insight, Oncology/Biopharmaceuticals in GSK’s US managed care division. Ben was VP Global Commercial and Product Strategy, Oncology, and accountable for global launches and product management, scientific communications, and health outcomes for GSK’s oncology portfolio. Product responsibilities included therapeutic and supportive care products such as Votrient®, Tykerb®, Arzerra®, Arranon®, and Promacta® as well as many discovery and development stage products. Before joining GSK, he worked in senior roles at Exocell, a development stage biotechnology company, and Eastman Pharmaceuticals/Sterling Winthrop (now Sanofi).